A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Public ClinicalTrials.gov record NCT07553299. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Identify the Optimal Weekly Oral Dose of Ecnoglutide (VRB-101) for Maintaining Body Weight in Participants With Obesity or Overweight Who Have Weight-Related Comorbidities
Study identification
- NCT ID
- NCT07553299
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Verdiva Bio Dev Limited
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- VRB-101 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2026
- Primary completion
- Nov 29, 2026
- Completion
- Dec 30, 2026
- Last update posted
- Apr 27, 2026
2026
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Study Site 202 | Cullman | Alabama | 35055 | — |
| Clinical Study Site 203 | Phoenix | Arizona | 85028 | — |
| Clinical Study Site 212 | Tempe | Arizona | 85281 | — |
| Clinical Study Site 201 | Little Rock | Arkansas | 72205 | — |
| Clinical Study Site 214 | Santa Maria | California | 93454 | — |
| Clinical Study Site 216 | Stamford | Connecticut | 06905 | — |
| Clinical Study Site 204 | Bradenton | Florida | 34209 | — |
| Clinical Study Site 215 | St. Petersburg | Florida | 33704 | — |
| Clinical Study Site 213 | El Dorado | Kansas | 67042 | — |
| Clinical Study Site 210 | Petal | Mississippi | 39465 | — |
| Clinical Study Site 205 | Buffalo | New York | 14217 | — |
| Clinical Study Site 206 | Lenoir | North Carolina | 28645 | — |
| Clinical Study Site 209 | Jackson | Tennessee | 38305 | — |
| Clinical Study Site 217 | Houston | Texas | 77008 | — |
| Clinical Study Site 211 | Houston | Texas | 77040 | — |
| Clinical Study Site 218 | Irving | Texas | 75063 | — |
| Clinical Study Site 207 | Richmond | Virginia | 23226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07553299, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07553299 live on ClinicalTrials.gov.